Paraneoplastic Neuromuscular Syndromes
Paraneoplastic neuromuscular syndromes arise from immune responses directed against antigens shared between tumors and the peripheral nervous system, neuromuscular junction, or muscle. These disorders frequently precede cancer diagnosis and span a wide clinical spectrum — from sensory neuronopathy and Lambert-Eaton myasthenic syndrome (LEMS) to inflammatory myopathies. The 2021 PNS-Care criteria replaced the term “onconeural antibodies” with a risk-stratified classification: high-risk antibodies (>70% cancer association, typically targeting intracellular antigens) and intermediate-risk antibodies (30–70% cancer association, often targeting cell-surface antigens). Recognizing paraneoplastic neuromuscular presentations is critical because neurologic symptoms frequently herald an occult malignancy, and early cancer detection and treatment remain the most important determinants of neurologic outcome.
Bottom Line
- Antibody classification: High-risk antibodies (anti-Hu, anti-CV2/CRMP5, anti-amphiphysin, anti-Yo) target intracellular antigens and carry >70% cancer association; intermediate-risk antibodies (P/Q-type VGCC, GABABR, AMPAR) target cell-surface antigens with 30–70% cancer risk
- Paraneoplastic neuropathy: Sensory neuronopathy (anti-Hu/ANNA-1) is the most characteristic presentation — asymmetric, painful, non-length-dependent, strongly associated with SCLC; sensorimotor and autonomic variants also occur
- LEMS: 50–60% paraneoplastic (SCLC); defined by P/Q-type VGCC antibodies, proximal weakness with areflexia, autonomic dysfunction, and incremental response on high-frequency repetitive nerve stimulation
- Dermatomyositis: Cancer risk 15–30% overall; anti-TIF1-γ and anti-NXP-2 antibodies identify 83% of cancer-associated cases and warrant intensive malignancy screening
- Timing: Neuromuscular symptoms precede cancer diagnosis in the majority of paraneoplastic cases; the PNS-Care criteria recommend cancer screening every 4–6 months for up to 2 years when initial workup is negative
- Treatment hierarchy: Cancer treatment is the primary intervention; immunotherapy (IVIg, plasma exchange, corticosteroids, rituximab) and symptomatic agents (3,4-DAP for LEMS) are adjunctive
Overview and Diagnostic Framework
Paraneoplastic vs. Primary Autoimmune Disease
Neuromuscular disorders can occur as paraneoplastic phenomena or as primary autoimmune conditions without an underlying malignancy. The distinction carries significant implications for cancer screening, prognosis, and treatment. Paraneoplastic syndromes are driven by immune responses against tumor-expressed antigens that cross-react with nervous system components. Antibodies targeting intracellular antigens (e.g., anti-Hu, anti-Yo, anti-CV2/CRMP5, anti-amphiphysin) reflect cytotoxic T-cell-mediated damage and carry the highest cancer risk, whereas antibodies targeting cell-surface or synaptic proteins (e.g., VGCC, GABABR) are more likely to be directly pathogenic and may occur with or without cancer.
PNS-Care 2021 Diagnostic Criteria
The 2021 PNS-Care update refined the diagnostic approach to paraneoplastic neurologic syndromes, replacing the 2004 framework with a scoring system that combines clinical phenotype, antibody risk category, cancer presence, and follow-up duration. The panel classified three levels of diagnostic certainty:
PNS-Care Diagnostic Levels
- Definite PNS (score ≥8): High- or intermediate-risk clinical phenotype + high- or intermediate-risk antibody + documented cancer within 2 years of neurologic onset
- Probable PNS (score 6–7): Compatible phenotype and antibody present without cancer confirmed (or cancer diagnosed >2 years after neurologic onset)
- Possible PNS (score ≤5): One criterion present, or cancer diagnosed >2 years after onset without initial antibody identification
High-risk neuromuscular phenotypes include sensory neuronopathy, Lambert-Eaton myasthenic syndrome, and gastrointestinal pseudo-obstruction. The criteria recommend cancer screening every 4–6 months for up to 2 years when high-risk antibodies are detected.
Paraneoplastic Neuropathies
Sensory Neuronopathy (Anti-Hu/ANNA-1)
Paraneoplastic sensory neuronopathy is the most characteristic neuropathic presentation of paraneoplastic disease and a high-risk phenotype in the PNS-Care criteria. It results from immune-mediated destruction of dorsal root ganglion neurons and is most strongly associated with anti-Hu (ANNA-1) antibodies and small cell lung cancer (SCLC).
- Clinical features: Asymmetric, painful, non-length-dependent sensory loss; prominent proprioceptive deficit leading to sensory ataxia and pseudoathetosis; areflexia; subacute onset over days to weeks
- Cancer association: 81% of ANNA-1-positive patients are found to have SCLC; in 97% of cases, neurologic symptoms precede cancer diagnosis
- Electrodiagnostic findings: Absent or markedly reduced sensory nerve action potentials (SNAPs) with preserved motor conduction studies; axonal pattern on nerve conduction studies in 47% and mixed axonal-demyelinating in 18%
- CSF: Frequently abnormal with lymphocytic pleocytosis and elevated protein, even when only peripheral nervous system involvement is apparent
- Treatment response: Generally poor; corticosteroids, IVIg, plasma exchange, and cyclophosphamide have shown limited neurologic benefit; cancer treatment offers the best chance of stabilization
Sensorimotor Neuropathy (Anti-CV2/CRMP5, Anti-Amphiphysin)
Paraneoplastic sensorimotor neuropathies present as painful, often asymmetric polyradiculoneuropathies. CRMP5-IgG (anti-CV2) is found in 42% of positive patients presenting with neuropathy, and 96% develop neurologic symptoms before cancer diagnosis. The most common underlying malignancy is SCLC (75%), followed by thymoma (15%). Amphiphysin antibodies are associated with breast adenocarcinoma (63%) and SCLC (22%), with neuropathy often coexisting with CNS manifestations such as stiff person syndrome or encephalomyelitis. Electrophysiologic studies show an axonal process. IV corticosteroids are most consistently associated with stabilization of neuropathy impairment scores among available immunotherapies.
Autonomic Neuropathy
Paraneoplastic autonomic neuropathy may occur in isolation or accompany sensory neuronopathy. Anti-Hu antibodies are the most common association, reflecting involvement of autonomic ganglia. Ganglionic acetylcholine receptor (gAChR) antibodies can also mediate autoimmune autonomic ganglionopathy, with a paraneoplastic subset associated with SCLC and thymoma. Clinical features include orthostatic hypotension, gastroparesis, constipation or pseudo-obstruction, urinary retention, and sudomotor dysfunction. Gastrointestinal pseudo-obstruction is classified as a high-risk phenotype in the PNS-Care criteria.
Vasculitic Neuropathy with Malignancy
Vasculitis can complicate malignancy as a secondary systemic vasculitis. Neuropathy in this setting typically presents as mononeuritis multiplex with stepwise, asymmetric deficits involving both motor and sensory fibers. Hematologic malignancies, lymphomas, and solid tumors (particularly lung) are the most frequent associations. Nerve biopsy shows necrotizing vasculitis of epineurial or endoneurial blood vessels with axonal degeneration. Treatment is directed at both the underlying malignancy and the inflammatory process, usually requiring corticosteroids with or without cyclophosphamide or rituximab.
Lambert-Eaton Myasthenic Syndrome
Lambert-Eaton myasthenic syndrome is a presynaptic disorder of neuromuscular transmission caused by antibodies against P/Q-type voltage-gated calcium channels (VGCCs) on motor nerve terminals. Approximately 50–60% of LEMS cases are paraneoplastic, with SCLC accounting for the vast majority. The remaining 40–50% are classified as autoimmune LEMS without detectable malignancy.
LEMS Clinical Triad
- Proximal muscle weakness: Insidious onset, typically beginning in the lower limbs; fatigable but with transient improvement after brief maximal effort (Lambert sign); bulbar and respiratory muscles less commonly affected than in myasthenia gravis
- Areflexia with post-exercise facilitation: Hyporeflexia or areflexia at rest; reflexes may transiently return after sustained isometric contraction of the tested muscle — a hallmark feature distinguishing LEMS from other causes of hyporeflexia
- Autonomic dysfunction: Dry mouth (most common), constipation, erectile dysfunction, orthostatic hypotension, and impaired sweating; present in up to 80% of patients
Diagnosis
- Serology: P/Q-type VGCC antibodies are present in ~85–90% of LEMS patients; N-type VGCC antibodies may coexist. SOX1 antibodies carry 95% specificity for SCLC and are found in 64% of patients with cancer-associated LEMS
- Repetitive nerve stimulation (RNS): Low compound muscle action potential (CMAP) amplitudes at rest; ≥10% decremental response at 2–3 Hz low-frequency stimulation; ≥100% incremental response at 20–50 Hz high-frequency stimulation or after 10 seconds of maximal voluntary contraction — the electrophysiologic hallmark of LEMS
- Cancer screening: CT chest is mandatory; PET-CT is recommended if initial CT is negative; screening should be repeated every 6 months for at least 2 years in VGCC-positive patients
Treatment
| Modality | Details |
|---|---|
| Cancer treatment | Primary intervention in paraneoplastic LEMS; chemotherapy and/or radiation for SCLC often improves neuromuscular function |
| 3,4-Diaminopyridine (3,4-DAP) | First-line symptomatic therapy; prolongs presynaptic action potential by blocking potassium channels, enhancing calcium influx and ACh release; FDA-approved (amifampridine) |
| Pyridostigmine | Mild adjunctive benefit; less effective than in myasthenia gravis due to presynaptic mechanism |
| IVIg | Short-term improvement demonstrated in randomized trials; used for acute exacerbations or as bridge therapy |
| Immunosuppression | Prednisone, azathioprine, mycophenolate, or rituximab for refractory autoimmune LEMS; used cautiously in paraneoplastic LEMS given immunosuppression concerns |
Paraneoplastic Myopathies
Dermatomyositis and Cancer
Dermatomyositis (DM) carries a well-established cancer association, with malignancy identified in 15–30% of adult DM patients. The cancer risk is highest in the first 1–3 years following diagnosis and increases with age, male sex, and specific myositis-specific antibodies. Ovarian, lung, gastrointestinal, breast, and nasopharyngeal carcinomas are the most commonly associated malignancies.
| Antibody | Cancer Association | Key Features |
|---|---|---|
| Anti-TIF1-γ (p155/140) | Highest risk; SIR = 17.3 | Present in >50% of cancer-associated DM; associated with severe cutaneous disease, dysphagia; screening mandatory |
| Anti-NXP-2 (MJ) | High risk; SIR = 8.1 | Associated with calcinosis (especially in younger patients); subcutaneous edema; cancer risk highest in adults >40 years |
| Anti-SAE | Intermediate risk | Severe cutaneous involvement often preceding myopathy; cancer screening recommended |
| Anti-Mi-2 | Low risk | Classic DM rash with good treatment response; relatively favorable prognosis |
| Anti-MDA5 | Low cancer risk | Amyopathic DM; rapidly progressive interstitial lung disease; cutaneous ulceration |
Anti-TIF1-γ and anti-NXP-2 together identify 83% of cancer-associated DM cases. All adult patients with dermatomyositis — particularly those with these antibodies — require comprehensive age- and sex-appropriate malignancy screening at diagnosis and periodic re-screening for at least 3 years.
Immune-Mediated Necrotizing Myopathy
Immune-mediated necrotizing myopathy (IMNM) is characterized by acute or subacute proximal weakness, markedly elevated CK levels, and myopathic findings on EMG. Biopsy shows necrotic and regenerating fibers with minimal inflammatory infiltrate. The two primary antibody associations are anti-SRP and anti-HMGCR. While statin exposure is the most recognized trigger for anti-HMGCR myopathy, a paraneoplastic subset exists — particularly in older patients without statin exposure or those with anti-SRP antibodies. Cancer screening should be performed in older adults presenting with IMNM, especially when antibody-negative or when the clinical context is atypical.
Paraneoplastic Motor Neuron Disease
Paraneoplastic motor neuron disease is rare and can mimic amyotrophic lateral sclerosis (ALS). Presentations include isolated lower motor neuron disease, upper motor neuron-predominant disease, or a mixed pattern. Anti-Hu (ANNA-1) and anti-amphiphysin antibodies are the most commonly reported associations, with SCLC as the predominant underlying malignancy. Distinguishing features from typical ALS include subacute onset, prominent sensory symptoms, CSF inflammatory changes, and the presence of paraneoplastic antibodies. Case reports document neurologic stabilization or improvement with cancer treatment and immunotherapy, underscoring the importance of paraneoplastic evaluation in atypical motor neuron presentations.
Comprehensive Antibody-Syndrome Table
| Antibody | NM Syndrome | Cancer Association | Treatment Response |
|---|---|---|---|
| Hu (ANNA-1) | Sensory neuronopathy, sensorimotor neuropathy, autonomic neuropathy, motor neuron disease | SCLC (81%) | Poor; cancer treatment primary |
| CV2/CRMP5 | Painful polyradiculoneuropathy, sensorimotor neuropathy | SCLC (75%), thymoma (15%) | IV corticosteroids may stabilize |
| Amphiphysin | Polyradiculoneuropathy, sensory neuronopathy, stiff person syndrome | Breast (63%), SCLC (22%) | Moderate; cyclophosphamide + IV steroids or IVIg |
| P/Q-type VGCC | Lambert-Eaton myasthenic syndrome | SCLC (50–60%) | Good; 3,4-DAP, cancer treatment, immunotherapy |
| SOX1 | LEMS (biomarker for cancer-associated LEMS) | SCLC (95% specificity) | Cancer treatment improves NM function |
| Ganglionic AChR | Autoimmune autonomic ganglionopathy | SCLC, thymoma (minority) | Variable; IVIg, plasma exchange |
| TIF1-γ | Dermatomyositis | Ovarian, lung, GI, breast (SIR 17.3) | Moderate; immunosuppression + cancer treatment |
| NXP-2 | Dermatomyositis | Various solid tumors (SIR 8.1) | Moderate; immunosuppression + cancer treatment |
| MAP1B | Painless polyradiculoneuropathy, sensory neuronopathy | Lung cancer (majority) | 50% respond to immunotherapy |
| NIF | Myeloradiculoneuropathy | Neuroendocrine carcinoma (~75%) | 77% immunotherapy responsive |
| LUZP4 | Motor neuronopathy, polyradiculopathy | Seminoma (vast majority) | Best with combined immunotherapy + cancer treatment |
Cancer Screening Protocol
Recommended Cancer Screening in Paraneoplastic NM Syndromes
- Initial workup (all patients): CT chest, abdomen, and pelvis with contrast; consideration of PET-CT if initial CT is unrevealing; complete blood count, metabolic panel, LDH, and age-appropriate tumor markers
- PET-CT: Superior sensitivity for detecting occult malignancies, especially small or metabolically active tumors not visualized on conventional CT; recommended as second-line or first-line in high-risk antibody-positive patients
- Sex-specific screening: Mammography and pelvic ultrasound in women (especially with anti-amphiphysin or anti-Yo); testicular ultrasound in men under 50 (especially with anti-Ma2 or anti-LUZP4)
- Repeat screening if initially negative: Every 4–6 months for 2 years in patients with high-risk antibodies (PNS-Care recommendation); annual screening for an additional 2–4 years in intermediate-risk categories
- Age-appropriate cancer screening: Colonoscopy, PSA (men), Pap smear (women), and dermatologic examination should be current and up to date
- Antibody-guided screening: Anti-Hu and VGCC → prioritize chest imaging for SCLC; anti-amphiphysin → breast imaging; anti-TIF1-γ/NXP-2 → broad malignancy search including ovarian, GI, and lung; anti-LUZP4/Ma2 → testicular ultrasound
Critical Clinical Warning
- Neuromuscular symptoms precede cancer diagnosis by months to years in the majority of paraneoplastic cases — in 97% of anti-Hu-positive patients, neurologic symptoms antedate cancer detection
- A negative initial cancer screen does not exclude malignancy; the PNS-Care criteria mandate repeat screening every 4–6 months for at least 2 years
- Patients with high-risk antibodies (anti-Hu, anti-CV2/CRMP5, anti-amphiphysin) and a compatible neuromuscular phenotype should be treated as having probable PNS even before cancer is identified
- Immune checkpoint inhibitor therapy can trigger or worsen paraneoplastic neuromuscular syndromes; approximately 50% of patients with pre-existing PNS experience neurologic deterioration during ICI treatment
- Coexistence of multiple paraneoplastic antibodies is common and may indicate a higher likelihood of malignancy or more than one concurrent tumor; comprehensive panel testing is recommended over single-antibody assays
Treatment Principles
The treatment of paraneoplastic neuromuscular syndromes follows a hierarchical approach. Early identification and treatment of the underlying malignancy is the single most important intervention — tumor removal or cytoreduction reduces the antigenic stimulus driving the immune response. Immunotherapy serves as an adjunct and includes IVIg, plasma exchange, corticosteroids, and steroid-sparing agents (rituximab, cyclophosphamide, azathioprine, mycophenolate). Treatment response varies substantially by antibody type: cell-surface antibody-mediated disorders (LEMS, ganglionic AChR) generally respond better to immunotherapy than intracellular antibody-mediated conditions (anti-Hu sensory neuronopathy), where cytotoxic T-cell-mediated neuronal destruction causes irreversible damage. Symptomatic therapy — 3,4-DAP for LEMS, neuropathic pain management for sensory neuronopathy, and physical rehabilitation — should be initiated concurrently. Multidisciplinary coordination between neurology, oncology, and rehabilitation medicine is essential for optimal outcomes.
References
- Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1014.
- Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998;50(3):652-657.
- Camdessanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain. 2002;125(Pt 1):166-175.
- Dubey D, Lennon VA, Gadoth A, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018;90(2):e103-e110.
- Dubey D, Jitprapaikulsan J, Bi H, et al. Amphiphysin-IgG autoimmune neuropathy: a recognizable clinicopathologic syndrome. Neurology. 2019;93(20):e1873-e1880.
- Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58(1):96-107.
- Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.
- Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (DELTA-P) score to predict cancer in patients with LEMS. Neurology. 2011;76(20):2009-2015.
- Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol. 2005;159(1-2):230-237.
- Sabater L, Titulaer MJ, Saiz A, et al. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70(12):924-928.
- Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2005;32(4):515-520.
- Trillenberg P, Rosenbohm A, Grußendorf M, et al. Diagnosis and treatment of Lambert-Eaton myasthenic syndrome. Pract Neurol. 2024;24(2):91-98.
- Oldroyd AGS, Allard AB, Callen JP, et al. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology. 2021;60(6):2615-2628.
- Fiorentino DF, Kuo K, Engstrom J, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65(11):2954-2962.
- Allenbach Y, Keraen J, Bouber AM, et al. Anti-TIF1-γ antibodies in dermatomyositis and cancer: clinical data. Rev Med Interne. 2014;35(7):444-451.
- Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8-23.
- Allenbach Y, Mammen AL, Benveniste O, Stenzel W. Immune-mediated necrotizing myopathies working group. 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Neuromuscul Disord. 2018;28(1):87-99.
- Vermaak E, Tansey CE, Tansey MG. Neuroinflammation and paraneoplastic motor neuron disease. Handb Clin Neurol. 2016;133:259-274.
- Jitprapaikulsan J, Paul P, Thakolwiboon S, et al. Paraneoplastic neurological syndrome: an evolving story. Neuro Oncol Pract. 2021;8(4):362-374.
- Tracy JA. Autoimmune axonal neuropathies. Continuum (Minneap Minn). 2024;30(5):1457-1487.
- Gadoth A, Kryzer TJ, Fryer J, et al. Microtubule-associated protein 1B: novel paraneoplastic biomarker. Ann Neurol. 2017;81(2):266-277.
- Dubey D, Kryzer T, Guo Y, et al. Leucine zipper 4 autoantibody: a novel germ cell tumor and paraneoplastic biomarker. Ann Neurol. 2021;89(5):1001-1010.
- Basal E, Zalewski N, Kryzer TJ, et al. Paraneoplastic neuronal intermediate filament autoimmunity. Neurology. 2018;91(18):e1677-e1689.
- Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56(5):715-719.
- Vogrig A, Joubert B, Maureille A, et al. Comprehensive analysis of paraneoplastic neurologic syndrome and PNS-CARE diagnostic criteria in clinical practice. Neurol Neuroimmunol Neuroinflamm. 2024;11(1):e200316.